Melanoma Clinical Trials in Minneapolis

Showing 101-120 of 211 trials

Study in Subjects With Small Primary Choroidal Melanoma

NCT03052127

The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.

Uveal MelanomaOcular MelanomaChoroidal Melanoma

Aura Biosciences57 participantsStarted Feb 2017

Tucson, Arizona, United States • Los Angeles, California, United States • Palo Alto, California, United States +10 more locations

RECRUITING< 1 mile

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

NCT03941379

The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and effectiveness in these subjects. This study will collect information from procedures conducted as part of routine follow-up eye care and cancer care. Additionally, the registry will collect all adverse events, information about pregnancy and symptomatic overdose.

Choroidal MelanomaIndeterminate Lesions of Eye

Aura Biosciences500 participantsStarted Mar 2019

Tucson, Arizona, United States • Los Angeles, California, United States • Palo Alto, California, United States +13 more locations

Study in Subjects With Small Primary Choroidal Melanoma

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Melanoma Trials in Other Cities

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker

Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Other Conditions in Minneapolis